UNCATEGORIZED
Pinealon vs Epithalon represents one of the most closely studied comparisons in Khavinson bioregulator peptide research. Both short-chain peptides were developed at the St. Petersburg Institute of Bioregulation and Gerontology under the direction of Professor Vladimir Khavinson, yet they differ markedly in sequence, tissue specificity, and the biological pathways investigated in preclinical models. This article reviews the published research on each compound strictly in a scientific context for researchers and life-science professionals.
All information below is drawn from peer-reviewed preclinical and in-vitro studies. Neither peptide has received regulatory approval for human therapeutic use, and nothing here constitutes medical advice or a recommendation for personal administration.
The Khavinson bioregulator framework, developed over several decades at the Institute of Bioregulation and Gerontology (St. Petersburg, Russia), posits that short peptides isolated from or modelled on tissue-specific proteins can act as “molecular signals” that modulate gene expression in a tissue-selective manner. This framework has generated a substantial body of preclinical literature, much of it published in the Bulletin of Experimental Biology and Medicine.
Pinealon (also written as Pinalon) carries the amino-acid sequence Glu-Asp-Arg (EDR), making it a tripeptide. It was originally derived from the polypeptide complex Cortagen and is considered pineal- and brain-targeted in preclinical models. Researchers have used it to study neuroprotection, retinal cell viability, and cognitive-related endpoints.
Epithalon (Epitalon) carries the sequence Ala-Glu-Asp-Gly (AEDG), making it a tetrapeptide. It was developed as a synthetic analogue of Epithalamin, a polypeptide extract of the pineal gland. Epithalon research has concentrated on telomere biology, pineal melatonin signalling, and longevity-associated endpoints in aged animal models.
For deeper background on each compound individually, see our dedicated research summaries: Pinealon: Neuroprotective Peptide Cognitive & Retinal Research and Epithalon: Telomeres & Anti-Aging Research Overview.
The table below summarises key parameters from published preclinical literature to help researchers contextualise each peptide’s studied properties.
| Parameter | Pinealon (EDR) | Epithalon (AEDG) |
|---|---|---|
| Peptide sequence | Glu-Asp-Arg (tripeptide) | Ala-Glu-Asp-Gly (tetrapeptide) |
| Molecular weight | ~418 Da | ~390 Da |
| Primary research focus | Neuroprotection, retinal cell viability, cognitive endpoints | Telomere elongation, pineal function, longevity biomarkers |
| Tissue targets in models | Brain, retina, pineal gland | Pineal gland, immune cells, somatic cell lines |
| Epigenetic mechanism studied | Chromatin remodelling; modulation of pro-apoptotic gene expression in neural cells | Chromatin decondensation; telomerase activation (TERT expression) |
| Key animal models | Rats (ageing, ischaemia), retinal-degeneration models | Rats, mice (aged inbred strains), fruit-fly longevity models |
| Cell-culture evidence | Neuronal and retinal pigment epithelium (RPE) cell lines | Human fetal fibroblasts, somatic cell cultures from aged donors |
| Notable biomarkers studied | Caspase-3 activity, BDNF expression, retinal thickness | Telomere length (FISH/PCR), melatonin output, oxidative stress markers |
| Primary citation source | Khavinson VKh et al., Bull Exp Biol Med (multiple publications) | Khavinson VKh et al., Bull Exp Biol Med; Ann N Y Acad Sci |
| Research stage | Preclinical / in-vitro only | Preclinical / in-vitro; limited Phase I safety data (Russia) |
A recurring theme in Khavinson’s published work is that short bioregulator peptides may exert effects by interacting with histone-DNA complexes, thereby influencing chromatin compaction and downstream gene transcription. This hypothesis has been explored for both Pinealon and Epithalon using spectroscopic and X-ray diffraction techniques in cell-free systems.
For Pinealon, Khavinson VKh et al. (Bull Exp Biol Med, 2012) reported that the EDR tripeptide showed specific binding affinity to double-stranded DNA segments enriched in CpG islands, with modelled interactions suggesting influence over transcription-factor binding sites relevant to neuronal survival pathways. In aged rat neuronal cultures, Pinealon was associated with reduced expression of pro-apoptotic markers including caspase-3 and Bax, consistent with a chromatin-level regulatory effect, though causality remains to be firmly established in higher-order models.
For Epithalon, a landmark study by Khavinson VKh et al. (Bull Exp Biol Med, 2003) demonstrated that AEDG peptide treatment of human fetal fibroblast cultures was associated with telomere elongation and increased telomerase (TERT) activity versus untreated controls. The authors proposed that Epithalon may decondense chromatin in the region of the TERT gene promoter, thereby allowing increased transcription. Independent replication of these findings in validated Western laboratory settings is still pending.
Both peptides therefore share a proposed chromatin-interaction mechanism, but the downstream gene targets differ substantially: Pinealon research emphasises neuroprotective and anti-apoptotic gene networks, while Epithalon research emphasises telomere maintenance and pineal hormone regulation.
Researchers interested in sourcing these compounds for laboratory investigation can view the available reference materials at the Pinealon product page and the Epithalon product page on Biohacker Team.
The breadth and type of study models differ between the two peptides, which is important context when evaluating the quality of available evidence. Our research team — with specialist background in peptide biochemistry and preclinical pharmacology — has reviewed the primary literature to provide the summary below. All compounds supplied by Biohacker Team are authenticated by third-party certificate-of-analysis (CoA) testing to ensure purity and sequence integrity before dispatch to research institutions.
Pinealon research models include:
Epithalon research models include:
The Institute of Bioregulation and Gerontology — the primary institution behind this research body — has published over 750 peer-reviewed papers on short bioregulator peptides since the 1970s. This positions the Khavinson group as among the most prolific contributors to short-peptide preclinical science globally, though much of the work has yet to be independently replicated in Western academic centres, a recognised limitation in the field.
Biohacker Team’s specialist curation team cross-references available PubMed-indexed literature when selecting which peptide compounds to stock, ensuring that every product offered reflects a genuine body of peer-reviewed preclinical investigation rather than purely commercial interest. Researchers can request copies of relevant publications or CoA documentation directly through the product pages.
Investigators considering either compound for a new preclinical protocol should weigh several practical factors beyond the published biological data.
Solubility and formulation: Both Pinealon (EDR) and Epithalon (AEDG) are water-soluble peptides that are typically reconstituted in sterile bacteriostatic water or phosphate-buffered saline (PBS) for in-vitro or in-vivo use. Their small size (under 500 Da) generally means acceptable membrane permeability in cell-culture models, though blood-brain barrier penetration data in vivo remains limited and should not be assumed without confirmatory studies.
Dosing ranges in published literature: Published rodent studies involving Epithalon have used doses ranging from approximately 0.1 mg/kg to 1 mg/kg administered intraperitoneally or subcutaneously over multi-week protocols. Pinealon in-vitro concentrations in cell-culture studies have ranged from 10 nM to 100 nM depending on the endpoint measured. Researchers should independently review primary sources and not extrapolate across species without appropriate pharmacokinetic modelling.
Storage conditions: Both peptides should be stored lyophilised at −20 °C with desiccation, away from repeated freeze-thaw cycles. Once reconstituted, solutions should be used within 48–72 hours or aliquoted and re-frozen. These are general guidance points; researchers should follow their institutional SOPs and the CoA provided with each batch.
Endpoint selection: Given the distinct research niches of the two peptides, endpoint selection is critical. For Pinealon-focused protocols, validated markers include caspase-3 and Bax/Bcl-2 ratio in neural models, BDNF ELISA in conditioned media, and retinal layer thickness via OCT in animal models. For Epithalon-focused protocols, telomere length quantification (q-FISH or qPCR-based assays), TERT mRNA expression, and melatonin ELISA from pineal tissue homogenates are the most commonly employed endpoints in the published literature.
Pinealon is a tripeptide (three amino acids: Glu-Asp-Arg, abbreviated EDR), whereas Epithalon is a tetrapeptide (four amino acids: Ala-Glu-Asp-Gly, abbreviated AEDG). Despite both being among the shortest bioregulator peptides studied by the Khavinson group, this one-amino-acid difference corresponds to distinct binding profiles and tissue-targeting patterns observed in preclinical models.
Neither Pinealon nor Epithalon has received approval from the FDA, EMA, or equivalent regulatory body for human therapeutic use. They are investigated as research chemicals in preclinical settings only. Biohacker Team supplies these peptides strictly for in-vitro and laboratory research purposes.
Both peptides have a substantial publication record through the Khavinson Institute, primarily in the Bulletin of Experimental Biology and Medicine. Epithalon arguably has a wider range of study models — including lifespan studies in rodents and Drosophila — while Pinealon’s literature is more concentrated in neural and retinal models. Researchers should consult PubMed and Google Scholar directly for the most current citation counts.
There is some overlap: both peptides have been studied in the context of ageing biology and both are proposed to act via chromatin-level mechanisms. However, their primary research niches differ. Pinealon is predominantly studied in neuroprotection and retinal health models, while Epithalon is predominantly studied in telomere biology and pineal-gland function models. A researcher’s choice between them would depend on the specific biological pathway under investigation.
No published peer-reviewed data currently describes a co-administration protocol for Pinealon and Epithalon in the same model system. Combination use in research would require independent ethical approval and rigorous experimental design. Researchers should review all available literature and consult with institutional review boards before designing any novel protocol.
Research-grade Pinealon and Epithalon peptides for in-vitro and preclinical laboratory use are available through specialist suppliers. Biohacker Team provides certificate-of-analysis documentation and purity specifications for both compounds. See the Pinealon research page and Epithalon research page for current availability.
Disclaimer: All content on this page is intended solely for informational and educational purposes in a scientific research context. Pinealon and Epithalon are not approved drugs or medical treatments. They are not intended for human consumption, self-administration, or veterinary use outside of licensed research settings. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendations. Researchers must comply with all applicable local, national, and international regulations governing the acquisition and use of research chemicals. Biohacker Team supplies these compounds exclusively to qualified researchers for legitimate laboratory research purposes.